undamentalytics Newsletter
Sign in

Madrigal Pharmaceuticals, Inc. revenue

Madrigal Pharmaceuticals, Inc.'s revenue was $958m in fiscal 2025, up 432.1% on the year before. Since fiscal 2012 ($147,000) it has grown at a compound 165.3% a year. Over the last twelve months it was $1.43bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue000000001809581,428
Growth on the year before—−100.0%———————+432.1%—
Gross profit——————00174——
Gross margin————————96.5%——

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Madrigal Pharmaceuticals, Inc. $1.43bn 92.8% —
Insmed Inc $1.52bn 240.0% 75.6%
Lakefront Biotherapeutics NV $1.26bn 321.6% —
Halozyme Therapeutics, Inc. $1.66bn 41.2% 29.1%
Alkermes plc. $1.75bn 15.3% 3.3%
PTC Therapeutics, Inc. $1.16bn -35.1% 13.1%

Compare with peers

Head to head: INSM vs MDGLLKFT vs MDGLHALO vs MDGLALKS vs MDGL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Madrigal Pharmaceuticals, Inc.